Does Excellus BCBS cover Wegovy for Heart Disease Risk Reduction?

Qualification pathways

You can qualify through any one of these.

Documentation to bring

• Baseline BMI documentation (≥27 kg/m²)
• Progress notes demonstrating established CVD (prior MI, prior stroke, symptomatic PAD with ABI <0.85, prior peripheral arterial revascularization, or amputation due to atherosclerotic disease)
• Prescriber attestation that Wegovy is prescribed by or in consultation with a cardiologist or neurologist
• Documentation that patient is currently a non-smoker (not smoked in past 6 months)
• Documentation that patient is partaking in a heart healthy diet
• Documentation that patient is engaging in physical activity at their level of ability
• Documentation of patient commitment to continue lifestyle modifications while on Wegovy
• Documentation that patient is optimized on standard of care for secondary CVD prevention (lipid-lowering, blood-pressure-lowering, SGLT2i when appropriate, antiplatelet when appropriate)
• Documentation that patient has no diagnosis of diabetes mellitus, ESRD, or NYHA Class IV heart failure
• At recertification: documentation of ≥80% PDC since last approval
• At recertification: documentation of continued non-smoker status, heart-healthy diet, and physical activity

Quantity limits

• 0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg — 4 pens per 28 days (Wegovy HD 7.2mg NOT approved for CV risk reduction indication); Maximum 14 twenty-eight-day supplies OR 5 eighty-four-day supplies per 365 days (84-day)
• 1.5mg tablet, 4mg tablet, 9mg tablet, 25mg tablet — 30 tablets per 30 days; Maximum 14 thirty-day supplies OR 5 ninety-day supplies per 365 days (84-day)

Approval and renewal

• Initial approval: 7 months
• Renewal: every 6 months
• Renewal: Upon recertification: patient must be utilizing 2.4mg OR 1.7mg injection OR 25mg tablet as maintenance dose; must demonstrate ≥80% PDC (Percent Days Covered) since last approval; must still be a non-smoker, partaking in a heart healthy diet and engaging in physical activity; must not have developed type 2 diabetes, ESRD, or NYHA Class IV heart failure symptoms. Note: GDMT optimization and CVD diagnosis are not explicitly re-verified at continuation per policy text.
• Renewal: At least 17 weeks on therapy before the first renewal.
• Renewal: Staying on a maintenance dose of at least 1.7 mg.

Not covered when

• Diabetes mellitus diagnosis excludes from this indication (consider GLP-1 agonists FDA-approved for CV risk reduction in T2DM instead)
• End-stage renal disease diagnosis excludes from this indication
• NYHA Class IV heart failure symptoms exclude from this indication
• Combination with other GIP and/or GLP-1 receptor agonists not approved (Exenatide, Victoza, Ozempic, Rybelsus, Trulicity, Mounjaro)
• Combination with any weight loss drugs (Rx, OTC, or herbal) not approved
• Wegovy HD 7.2mg not approved for this indication

Exceptions

• New York: All utilization management requirements compliant with applicable New York State insurance laws and regulations

Policy note: Standards of care for secondary CVD prevention may include lipid-lowering therapies, blood pressure-lowering therapy, SGLT2 inhibitors when appropriate, and antiplatelet therapy when appropriate — prescriber determines optimization. Wegovy HD 7.2mg explicitly NOT approved for this indication. For patients with type 2 diabetes seeking CV risk reduction, policy directs to GLP-1 agonists FDA-approved for MACE reduction in T2DM. BMI thresholds may be adjusted for Asian population (≥25 kg/m² suggests clinical obesity) on case-by-case basis. Annual GLP-1 day-supply limits apply cumulatively across all products.

verified June 5, 2026 · source: Weight Management Policy Pdf · View policy document (PDF)